Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 12Terminated 3Withdrawn 2Recruiting 2No longer available 2Active not recruiting 2

Sponsor Class

OTHER 7NIH 6INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Follicular 2

Interventions

pembrolizumab 184Carboplatin 132Paclitaxel 101Cisplatin 101Gemcitabine 86Pemetrexed 79durvalumab 75Nivolumab 66Docetaxel 56atezolizumab 52Bevacizumab 50Cyclophosphamide 49Dexamethasone 45Capecitabine 45Oxaliplatin 43130-nm albumin-bound paclitaxel 41Rituximab 40Fulvestrant 39Lenalidomide 38Fluorouracil 38Prednisone 32osimertinib 31olaparib 29Leucovorin 29venetoclax 28fludarabine 28Trastuzumab 27Doxorubicin 27Etoposide 25Cetuximab 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × INDUSTRY × tazemetostat × Clear all
NCT04224493 2026-06-01

SYMPHONY-1

Ipsen

Phase 3 Active not recruiting
599 enrolled
Lymphoid

Lymphoma, Follicular

NCT05228158 2026-01-02

A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in Japan

Eisai Inc.

Active not recruiting
145 enrolled
Lymphoid

Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡